Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 55Recurrence 6Lymphoma, Mantle-Cell 5Leukemia, Myeloid, Acute 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Lymphoma 3Plasmacytoma 2Neoplasms 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × POEMS Syndrome × ixazomib × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡